Solventum (SOLV) 3M’s (MMM) healthcare spinoff, on Thursday announced an agreement to acquire Acera Surgical, a privately owned wound care company, in an all-cash deal worth up to $850M.
Headquartered in St. Louis, Missouri, Acera makes synthetic treatments for soft tissue repair. Backed by its Restrata wound care products, the company is expected to generate roughly $90M in sales this year.
Solventum (SOLV) said it will utilize its cash on hand to fund the deal, which involves an upfront payment of $725M and up to $125M in additional payments pending the achievement of certain milestones.
The transaction is expected to close in H1 2026 and be slightly dilutive to the company’s adjusted EPS in 2026 and accretive to adjusted EPS from 2027.
Concurrently, Maplewood, Minnesota-based Solventum (SOLV) announced a new share repurchase program to buy back up to $1B of its common stock starting in 2026.